PEG conjugates of NK4

Details PEG conjugates of NK4 PEG conjugates of NK4

2007-10-10

2010-12-07

Landsman, Robert (Department: 1646)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S350000

Reexamination Certificate

active

07846896

ABSTRACT:
The present invention provides a conjugate consisting essentially of a NK4 molecule and a polyethylene glycol group having a molecular weight of from about 20 to about 40 kDa. The invention also provides a composition in which the monoPEGylated conjugates comprise at least 90% of the total of pegylated NK4 molecules and unpegylated NK4 molecules in the composition. Also provided is a composition in which the monoPEGylated conjugates comprise conjugates in which the PEG groups are attached to groups randomly selected from the lysine side chains of NK4 molecules and the N-terminal amino groups of NK4 molecules. A method for the treatment of cancer by administering 1 to 30 mg monoPEGylated NK4 per kg per day is further provided.

REFERENCES:
patent: 5766581 (1998-06-01), Bartley et al.
patent: 5977310 (1999-11-01), Namiki et al.
patent: 6025324 (2000-02-01), Bailon et al.
patent: 6340742 (2002-01-01), Burg et al.
patent: 6528485 (2003-03-01), Veronese et al.
patent: 6583272 (2003-06-01), Bailon
patent: 2002/0115833 (2002-08-01), Burg et al.
patent: 0 741 187 (1996-11-01), None
patent: 0 816 381 (1998-01-01), None
patent: 08 16381 (1998-07-01), None
patent: 1 064 951 (2001-01-01), None
patent: WO 93/23541 (1993-11-01), None
patent: WO 94/13322 (1994-06-01), None
patent: 9611953 (1996-04-01), None
patent: WO 98/31383 (1998-07-01), None
patent: 99/43813 (1999-09-01), None
patent: WO 99 55377 (1999-11-01), None
patent: WO 00 21574 (2000-04-01), None
Date, K., et al., FEBS Letters vol. 420 (1997) pp. 1-6.
Date, K., et al., Oncogene (1998) vol. 17 pp. 3045-3054.
Kuba, K., et al. Cancer Research (2000) vol. 60, pp. 6737-6743.
Uematsu Y., et al., Journal of Pharmaceutical Sciences (Jan. 1999), vol. 88 No. 1, pp. 131-135.
Gaertner, H., et al., Bioconjugate Chem. (1996) vol. 7 pp. 38-44.
Francis, G.E., et al., International Journal of Hematology, vol. 68 (1998) pp. 1-18.
Tsutsumi, Y. et al. Thrombosis & Haemostasis vol. 77, No. 1 (1997) pp. 168-173.
Tsutsumi, Y. et al., Proceedings of the National Academy of Sciences of the United States, vol. 97, No. 15 (Jul. 18, 2000) pp. 8548-8553).
Heinzerling, L., et al., Dermatology (2000) vol. 201, pp. 154-157.
Tsutsumi, Y. et al., Journal of Pharmacology & Experimental Therapeutics vol. 278 No. 3 (1996) pp. 1006-1011.
Reddy, R., et al. Annals of Pharmacotherapy vol. 34, No. 7-8 (Jul. 2000) pp. 915-923.
Bailon, P., Bioconjugate Chem. vol. 12 (Feb. 16, 2001) pp. 195-202.
Parr, C., et al., Int. J. Cancer vol. 85 (2000) pp. 563-570.

Affiliated with

Also associated with

Rating

PEG conjugates of NK4 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with PEG conjugates of NK4, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PEG conjugates of NK4 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4228541